Is HUM or REGN cheaper?

On trailing earnings, REGN is cheaper: HUM trades at a 40.56 P/E and REGN at 14.92.

Which has grown faster, HUM or REGN?

Over the past five years, HUM grew revenue faster — HUM at a 11.71% CAGR versus REGN at 10.16%.

Does HUM or REGN pay a bigger dividend?

HUM yields 0.93% and REGN yields 0.59% based on trailing dividends and the latest price.

Is HUM or REGN more profitable?

REGN runs the higher net margin — HUM at 0.82% versus REGN at 29.65%.

Which has been the better investment, HUM or REGN?

Over the past 10-year, HUM delivered the higher annualized total return — HUM at 8.24% versus REGN at 5.19%. Past performance doesn't predict future results.

Humana Inc. (HUM) vs Regeneron Pharmaceuticals, Inc. (REGN)

REGN leads on 13 of 16 compared metrics.

A side-by-side comparison of Humana Inc. and Regeneron Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

Regeneron Pharmaceuticals, Inc.

$63.06B

$612.14Healthcare

Total return — HUM vs REGN

growth of $100 · last 30y

HUM +1977.9%REGN +3436.3%REGN compounded faster

HUM REGN

HUM vs REGN: by the numbers

•REGN is the larger company ($63.06B vs $45.53B market cap).
•REGN trades at the lower earnings multiple (14.92 vs 40.56 P/E).
•REGN converts more revenue to profit (29.65% vs 0.82% net margin).
•HUM grew revenue faster over the past five years (11.71% vs 10.16% CAGR).
•HUM pays the higher dividend yield (0.93% vs 0.59%).

Which is better, HUM or REGN?

Metric tally: HUM 3 · REGN 13

It depends on what you're optimizing for:

ValueREGN(lower P/E)

GrowthHUM(faster 5Y revenue CAGR)

IncomeHUM(higher dividend yield)

QualityREGN(higher ROIC)

Valuation

Metric	HUM	REGN
P/E ratio	40.56	14.92●
Forward P/E	23.94	11.30●
P/S ratio	0.33●	4.42
P/B ratio	2.46	2.10●
PEG ratio	—	3.38
EV / EBITDA	19.22	11.43●
FCF yield	2.78%	6.30%●

Profitability

Metric	HUM	REGN
Gross margin	14.01%	84.55%●
Operating margin	1.01%	24.32%●
Net margin	0.82%	29.65%●
ROE	6.08%	14.08%●
ROIC	3.12%	8.51%●

Dividends

Metric	HUM	REGN
Dividend yield	0.93%●	0.59%
Payout ratio	35.87%	8.45%

Growth (annualized)

Metric	HUM	REGN
Revenue CAGR (5Y)	11.71%●	10.16%
EPS CAGR (5Y)	-17.27%	5.70%●
FCF CAGR (5Y)	-17.19%	15.42%●
Total return CAGR (5Y)	-1.01%	3.26%●

Frequently asked

Which is better, HUM or REGN?: It depends on your goal. value: REGN (lower P/E); growth: HUM (faster 5Y revenue CAGR); income: HUM (higher dividend yield); quality: REGN (higher ROIC). Across all compared metrics, REGN leads 13 to 3.
Is HUM or REGN cheaper?: On trailing earnings, REGN is cheaper: HUM trades at a 40.56 P/E and REGN at 14.92.
Which has grown faster, HUM or REGN?: Over the past five years, HUM grew revenue faster — HUM at a 11.71% CAGR versus REGN at 10.16%.
Does HUM or REGN pay a bigger dividend?: HUM yields 0.93% and REGN yields 0.59% based on trailing dividends and the latest price.
Is HUM or REGN more profitable?: REGN runs the higher net margin — HUM at 0.82% versus REGN at 29.65%.
Which has been the better investment, HUM or REGN?: Over the past 10-year, HUM delivered the higher annualized total return — HUM at 8.24% versus REGN at 5.19%. Past performance doesn't predict future results.

Go deeper

Full HUM analysis Full REGN analysis Interactive comparison tool

Dig into the metrics

Humana P/E ratio Regeneron Pharmaceuticals P/E ratio Humana dividend yield Regeneron Pharmaceuticals dividend yield Humana ROE Regeneron Pharmaceuticals ROE Humana operating margin Regeneron Pharmaceuticals operating margin Humana revenue growth Regeneron Pharmaceuticals revenue growth Humana free cash flow Regeneron Pharmaceuticals free cash flow

Humana & Regeneron Pharmaceuticals appear in these rankings

Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.